Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world rhTNK-tPA for Acute Ischemic Stroke Within 4.5 Hours
ChiCTR2400091525Phase 4Recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenecteplase in ischemic stroke, sponsored by China-Japan Union Hospital of Jilin University. Primary endpoints: Proportion of patients with mRS 0–1 at Day 90 ± 7 and Incidence of symptomatic intracranial hemorrhage within 48 hours. Started Oct 2024; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400091525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091525.